VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 3, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-10-08
DOI
10.1038/srep02868
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model
- (2013) Jonathan McCafferty et al. ISME Journal
- Colorectal Cancer: Looking for Answers in the Microbiota
- (2013) Christian Jobin Cancer Discovery
- Interleukin-10 and Interleukin-10–Receptor Defects in Inflammatory Bowel Disease
- (2012) Neil Shah et al. CURRENT ALLERGY AND ASTHMA REPORTS
- Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy
- (2012) Daniel Kotlarz et al. GASTROENTEROLOGY
- Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans
- (2012) Nina Sanapareddy et al. ISME Journal
- The gut microbiota in IBD
- (2012) Chaysavanh Manichanh et al. Nature Reviews Gastroenterology & Hepatology
- Probiotic Bacteria Produce Conjugated Linoleic Acid Locally in the Gut That Targets Macrophage PPAR γ to Suppress Colitis
- (2012) Josep Bassaganya-Riera et al. PLoS One
- Immunoregulatory Mechanisms Underlying Prevention of Colitis-Associated Colorectal Cancer by Probiotic Bacteria
- (2012) Josep Bassaganya-Riera et al. PLoS One
- Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
- (2012) J. C. Arthur et al. SCIENCE
- Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer
- (2011) Caroline B. Appleyard et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- UCHIME improves sensitivity and speed of chimera detection
- (2011) Robert C. Edgar et al. BIOINFORMATICS
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
- (2011) A. D. Kostic et al. GENOME RESEARCH
- Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
- (2011) Tingting Wang et al. ISME Journal
- Microbial Dysbiosis in Colorectal Cancer (CRC) Patients
- (2011) Iradj Sobhani et al. PLoS One
- Enterobacteriaceae Act in Concert with the Gut Microbiota to Induce Spontaneous and Maternally Transmitted Colitis
- (2010) Wendy S. Garrett et al. Cell Host & Microbe
- Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2
- (2010) M. Schlee et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Prediction of In Vivo Short-Chain Fatty Acid Production in Hindgut Fermenting Mammals: Problems and Pitfalls
- (2010) S. Millet et al. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
- A Pyrosequencing Study in Twins Shows That Gastrointestinal Microbial Profiles Vary With Inflammatory Bowel Disease Phenotypes
- (2010) Ben P. Willing et al. GASTROENTEROLOGY
- The struggle within: Microbial influences on colorectal cancer
- (2010) Janelle C. Arthur et al. INFLAMMATORY BOWEL DISEASES
- Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis
- (2010) Joshua M. Uronis et al. INFLAMMATORY BOWEL DISEASES
- Probiotics and the gut microbiota in intestinal health and disease
- (2010) Mélanie G. Gareau et al. Nature Reviews Gastroenterology & Hepatology
- Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
- (2010) K. Atarashi et al. SCIENCE
- Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis
- (2009) Rudolf Mennigen et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Production of apoptosis-inducing substances from soybean protein by Clostridium butyricum: Characterization of their toxic effects on human colon carcinoma cells
- (2009) Hideki Arimochi et al. CANCER LETTERS
- The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis
- (2009) Ajit Sood et al. Clinical Gastroenterology and Hepatology
- Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine
- (2009) Petra Louis et al. FEMS MICROBIOLOGY LETTERS
- Regulatory T Cells Reinforce Intestinal Homeostasis
- (2009) Michael J. Barnes et al. IMMUNITY
- Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease
- (2009) C. Reiff et al. INFLAMMATORY BOWEL DISEASES
- Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
- (2009) Kendle M. Maslowski et al. NATURE
- Post-Translational Inhibition of IP-10 Secretion in IEC by Probiotic Bacteria: Impact on Chronic Inflammation
- (2009) Gabriele Hörmannsperger et al. PLoS One
- Modulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer Susceptibility
- (2009) Joshua M. Uronis et al. PLoS One
- Probiotics promote gut health through stimulation of epithelial innate immunity
- (2009) C. Pagnini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
- (2008) Yuri P. Rubtsov et al. IMMUNITY
- Role of probiotic therapy in IBD
- (2008) Kim Isaacs et al. INFLAMMATORY BOWEL DISEASES
- Analysis of bacterial bowel communities of IBD patients: What has it revealed?
- (2008) Harry Sokol et al. INFLAMMATORY BOWEL DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More